CENTOGENE Announces Appointment of Miguel Coego Rios as Chief Financial Officer
June 27 2022 - 4:01PM
Centogene N.V. (Nasdaq: CNTG), the
commercial-stage, essential biodata life science partner for rare
and neurodegenerative diseases, today announced the appointment of
Miguel Coego Rios as Managing Director and Chief Financial Officer
of the Company, effective June 22, 2022.
“As we continue to make progress on pivoting the organization to
focus on Core Business execution, we are very fortunate to have
someone of Miguel’s caliber and extensive experience to contribute
to our financial leadership and success. With more than a decade of
experience in senior finance roles in the biopharma sector, he will
be instrumental as we cement our position as the essential biodata
life science partner,” said Kim Stratton, CEO of CENTOGENE.
Miguel Coego Rios stated, "I am excited to formally assume
the position as CFO of CENTOGENE. We have been working diligently
to optimize operations and build a solid foundation to support our
future strategic direction, which is expected to position the
Company for growth in 2022 and beyond. My first priorities as the
CFO will be business and shareholder value creation, ensuring
financial health and best-in-class governance."
Mr. Coego Rios joined CENTOGENE as EVP Finance & Legal in
February 2022 and served as Interim Chief Financial Officer as of
April 1, 2022. He is a seasoned senior executive and has previously
served in finance and commercial leadership roles in the
pharmaceutical and biotech sectors. Prior to joining CENTOGENE, Mr.
Coego was Vice President & General Manager South Europe at
Orphazyme A/S, a late-stage clinical biotech. Before that he was
Vice President & CFO EMEA at Mundipharma, a multinational
pharmaceutical company. Earlier in his career, he served in several
senior management positions at Shire Pharmaceuticals between 2011
and 2019, most recently as CFO LATAM and General Manager of the
Andean region. Mr. Coego has gained notable international exposure
having completed positions in Colombia, Brazil, Spain, and the U.K.
He brings a proven track record in achieving sales and expense
targets, company management and development, and leading
multi-country projects to CENTOGENE.
About CENTOGENE
CENTOGENE engages in diagnosis and research around rare diseases
transforming real-world clinical, genetic, and multiomic data to
diagnose, understand, and treat rare diseases. Our goal is to bring
rationality to treatment decisions and to accelerate the
development of new orphan drugs by using our extensive rare disease
knowledge and data. CENTOGENE has developed a global proprietary
rare disease platform based on our real-world data repository of
over 650,000 individuals representing over 120 different
countries.
The Company’s platform includes epidemiologic, phenotypic, and
genetic data that reflects a global population, as well as a
biobank of patients’ blood samples and cell cultures. CENTOGENE
believes this represents the only platform focused on comprehensive
analysis of multi-level data to improve the understanding of rare
hereditary diseases. It allows for better identification and
stratification of patients and their underlying diseases to enable
and accelerate discovery, development, and access to orphan drugs.
As of December 31, 2021, the Company collaborated with over 30
pharmaceutical partners.
Follow us on LinkedIn
Forward-Looking Statements
This press release contains “forward-looking statements” within
the meaning of the U.S. federal securities laws. Statements
contained herein that are not clearly historical in nature are
forward-looking, and the words “anticipate,” “believe,”
“continues,” “expect,” “estimate,” “intend,” “project,” and similar
expressions and future or conditional verbs such as “will,”
“would,” “should,” “could,” “might,” “can,” and “may,” are
generally intended to identify forward-looking statements. Such
forward-looking statements involve known and unknown risks,
uncertainties, and other important factors that may cause
CENTOGENE’s actual results, performance, or achievements to be
materially different from any future results, performance, or
achievements expressed or implied by the forward-looking
statements. Such risks and uncertainties include, among others,
negative economic and geopolitical conditions and instability and
volatility in the worldwide financial markets, possible changes in
current and proposed legislation, regulations and governmental
policies, pressures from increasing competition and consolidation
in our industry, the expense and uncertainty of regulatory
approval, including from the U.S. Food and Drug Administration, our
reliance on third parties and collaboration partners, including our
ability to manage growth and enter into new client relationships,
our dependency on the rare disease industry, our ability to manage
international expansion, our reliance on key personnel, our
reliance on intellectual property protection, fluctuations of our
operating results due to the effect of exchange rates, our ability
to streamline cash usage, our requirement for additional financing,
or other factors. For further information on the risks and
uncertainties that could cause actual results to differ from those
expressed in these forward-looking statements, as well as risks
relating to CENTOGENE’s business in general, see CENTOGENE’s risk
factors set forth in CENTOGENE’s Form 20-F filed on March 31, 2022,
with the Securities and Exchange Commission (the “SEC”) and
subsequent filings with the SEC. Any forward-looking statements
contained in this press release speak only as of the date hereof,
and CENTOGENE’s specifically disclaims any obligation to update any
forward-looking statement, whether as a result of new information,
future events, or otherwise.
Media Contact:
CENTOGENE Lennart
Streibel Investor
Relations Investor.Relations@centogene.com
Ben Legg Corporate
Communications Press@centogene.com
Stern IR Suzanne Messere+1 (212)
698-8801suzanne.messere@sternir.com
Centogene NV (NASDAQ:CNTG)
Historical Stock Chart
From Mar 2024 to Apr 2024
Centogene NV (NASDAQ:CNTG)
Historical Stock Chart
From Apr 2023 to Apr 2024